10/18/2024

Janusmed sex and gender

Janusmed sex and gender – doxazosin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Doxazosin

Doxazosin

Class : A

Show all info

Print

Contact us

  1. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87.

  2. Kwon YH, Gwak HS, Yoon SJ, Chun IK. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 2007;33:824-9.

  3. Clinical Pharmacology and Biopharmaceutics Review - CARDURA XL (doxazosin mesylate). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2005-02-22, cited 2019-03-06].

  4. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension Results of the HALT Study Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7:848-52.

  5. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5:1957-64.

  6. Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. Int Urol Nephrol. 2011;43:645-9.

  7. Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. J Urol. 2009;182:2880-4.

  8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87.
  2. Kwon YH, Gwak HS, Yoon SJ, Chun IK. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 2007;33:824-9.
  3. Clinical Pharmacology and Biopharmaceutics Review - CARDURA XL (doxazosin mesylate). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2005-02-22, cited 2019-03-06].
  4. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension Results of the HALT Study Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7:848-52.
  5. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5:1957-64.
  6. Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. Int Urol Nephrol. 2011;43:645-9.
  7. Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. J Urol. 2009;182:2880-4.
  8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]